These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3259865)

  • 1. Brain dopamine receptors in schizophrenia: PET problems.
    Seeman P
    Arch Gen Psychiatry; 1988 Jun; 45(6):598-600. PubMed ID: 3259865
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.
    Seeman P; Niznik HB; Guan HC
    Arch Gen Psychiatry; 1990 Dec; 47(12):1170-2. PubMed ID: 2244801
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Seeman P
    Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022
    [No Abstract]   [Full Text] [Related]  

  • 4. PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Wong DF
    Neuropsychopharmacology; 1992 Aug; 7(1):69-72; discussion 73-5. PubMed ID: 1388023
    [No Abstract]   [Full Text] [Related]  

  • 5. No D2 receptor increase in PET study of schizophrenia.
    Farde L; Wiesel FA; Hall H; Halldin C; Stone-Elander S; Sedvall G
    Arch Gen Psychiatry; 1987 Jul; 44(7):671-2. PubMed ID: 2955770
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of two PET radioligands for imaging extrastriatal dopamine receptors in the human brain.
    Wang GJ; Volkow ND; Fowler JS; Wolf AP; MacGregor RR; Shea CE; Schlyer DJ; Hitzemann RJ
    Synapse; 1993 Nov; 15(3):246-9. PubMed ID: 8278901
    [No Abstract]   [Full Text] [Related]  

  • 7. The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics.
    Farde L; Wiesel FA; Nilsson L; Sedvall G
    Psychopharmacol Ser; 1989; 7():32-9. PubMed ID: 2574454
    [No Abstract]   [Full Text] [Related]  

  • 8. Positron emission tomography of brain dopamine D-2 receptors with 11C-raclopride in early Parkinson's disease.
    Laihinen A; Rinne JO; Någren K; Bergman J; Haaparanta M; Solin O; Ruotsalainen U; Rinne UK
    Acta Radiol Suppl; 1991; 376():151. PubMed ID: 1666759
    [No Abstract]   [Full Text] [Related]  

  • 9. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain.
    Seeman P; Guan HC; Niznik HB
    Synapse; 1989; 3(1):96-7. PubMed ID: 2521961
    [No Abstract]   [Full Text] [Related]  

  • 10. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.
    Hietala J; Syvälahti E; Vuorio K; Någren K; Lehikoinen P; Ruotsalainen U; Räkköläinen V; Lehtinen V; Wegelius U
    Arch Gen Psychiatry; 1994 Feb; 51(2):116-23. PubMed ID: 7905257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.
    Rinne UK; Laihinen A; Rinne JO; Någren K; Bergman J; Ruotsalainen U
    Mov Disord; 1990; 5(1):55-9. PubMed ID: 2136932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.
    Rinne JO; Laihinen A; Någren K; Bergman J; Solin O; Haaparanta M; Ruotsalainen U; Rinne UK
    J Neurosci Res; 1990 Dec; 27(4):494-9. PubMed ID: 1981915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic analysis of receptor binding with positron emission tomography.
    Eriksson L; Farde L; Rosenquist G
    Acta Radiol Suppl; 1991; 376():126-7. PubMed ID: 1666746
    [No Abstract]   [Full Text] [Related]  

  • 16. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis.
    Farde L; Eriksson L; Blomquist G; Halldin C
    J Cereb Blood Flow Metab; 1989 Oct; 9(5):696-708. PubMed ID: 2528555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
    Seeman P; Guan HC; Van Tol HH; Niznik HB
    Synapse; 1993 Aug; 14(4):247-53. PubMed ID: 8248849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.
    Dewey SL; Smith GS; Logan J; Brodie JD; Simkowitz P; MacGregor RR; Fowler JS; Volkow ND; Wolf AP
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11816-20. PubMed ID: 8265632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography.
    Hume SP; Myers R; Bloomfield PM; Opacka-Juffry J; Cremer JE; Ahier RG; Luthra SK; Brooks DJ; Lammertsma AA
    Synapse; 1992 Sep; 12(1):47-54. PubMed ID: 1411963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D4 receptors elevated in schizophrenia.
    Seeman P; Guan HC; Van Tol HH
    Nature; 1993 Sep; 365(6445):441-5. PubMed ID: 8413587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.